Navigation Links
Shanghai ChemPartner's Animal Facility Awarded AAALAC Accreditation

SHANGHAI, March 1 /PRNewswire-Asia/ -- Shanghai ChemPartner, a leading China-based contract research organization and a wholly-owned subsidiary of ShangPharma, today announced that its animal facility has received accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

AAALAC International is a private, non-profit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. As a result of an extensive on-site evaluation, AAALAC determined that Shanghai ChemPartner's animal facility is committed to the highest level of animal care and research practices.

AAALAC noted the following in its official approval letter: "The Shanghai ChemPartner management and staff are commended for providing sound facilities and programs for the care and use of laboratory animals. Especially noteworthy were the strong administrative commitment to the program, as evidenced by the financial support for the three well maintained, state-of-the-art animal facilities and equipment, as well as the highly capable and qualified animal resources staff; the active, conscientious, capable and very knowledgeable Institutional Animal Care and Use Committee (IACUC); the knowledgeable and experienced animal care and use staff; the dedication of a team who worked extremely well together to ensure responsible and appropriate animal care and use; the excellent documentation (Standard Operating Procedures and guidelines) and records, with attention to detail and completeness; and the good animal health. Therefore, FULL ACCREDITATION is awarded."

"The AAALAC accreditation comes as a result of our efforts in expanding service capabilities from chemistry to preclinical drug development including in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK) and toxicology," commented Michael Hui, founder and CEO of ChemPartner. "We are pleased to receive such high praise from the leading independent world body on the care and use of laboratory animals. We are confident of being an industry leader with the endorsement of AAALAC."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including more than 100 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies. Headquartered in China, ChemPartner has overseas business development operations in Boston, USA and Copenhagen, Denmark.

About ShangPharma

ShangPharma is a leading China-based outsourcing partner in pharmaceutical and biotechnology research and development, who provides customized services to international pharmaceutical, biotech, agrochemical and chemical companies. As the holding company of Shanghai ChemPartner Co., Ltd., Shanghai ChemExplorer Company Ltd., China Gateway Pharmaceutical (Shanghai) Ltd. and China Gateway Pharma Products (Chengdu) Ltd., ShangPharma offers global pharmaceutical, biotechnology and chemical companies comprehensive services and materials for their research and development needs. ShangPharma currently has a team of more than 1,800 professionals, and more than 60% of the employees have post graduate educational experience of Master or Ph.D. degrees. ShangPharma has established comprehensive R&D partnerships with world-class academic institutes, universities as well as healthcare industry and organizations, to contribute more added-value for its clients' success.

Further information is available at .

About AAALAC International

AAALAC International is a private, non-profit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. AAALAC stands for the "Association for Assessment and Accreditation of Laboratory Animal Care."

More than 800 companies, universities, hospitals, government agencies and other research institutions in 32 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use. These institutions volunteer to participate in AAALAC's program, in addition to complying with the local, state and federal laws that regulate animal research.

Further information is available at

SOURCE Shanghai ChemPartner

Back to top



SOURCE Shanghai ChemPartner
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):